The unresponsiveness of advanced cancers to the tumor-restricting properties of TGFβ is a consequence of either genetic mutations of downstream cytostatic genes that, otherwise, are induced by the pathway, or mutations in components of the core signaling pathway, such as TGFBR2 and SMAD4 [68]. This evidence concerns the gene TGFB1 and cancer.